Positive News SentimentPositive NewsNASDAQ:KROS Keros Therapeutics (KROS) News Today $30.85 0.00 (0.00%) (As of 10/4/2023 ET) Add Compare Share Share Today's Range$30.23▼$31.0650-Day Range$30.82▼$41.9752-Week Range$30.23▼$59.96Volume102,147 shsAverage Volume209,212 shsMarket Capitalization$915.01 millionP/E RatioN/ADividend YieldN/APrice Target$94.33 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineKeros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Societyfinance.yahoo.com - October 4 at 9:56 AMSG Americas Securities LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - September 30 at 4:12 AMWCM Investment Management LLC Purchases 11,187 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - September 24 at 6:40 AMCandriam S.C.A. Purchases 119,143 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - September 8 at 8:51 AMAmerican Century Companies Inc. Invests $4.82 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - September 7 at 4:46 AMWedbush Sticks to Their Buy Rating for Keros Therapeutics (KROS)markets.businessinsider.com - August 31 at 5:19 PMCitigroup Inc. Cuts Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - August 29 at 5:58 AMKeros Therapeutics, Inc. (NASDAQ:KROS) Stock Holdings Decreased by Barclays PLCmarketbeat.com - August 21 at 4:34 AMBenjamin Graham Detailed Fundamental Analysis - KROSnasdaq.com - August 20 at 9:12 PMKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by CHI Advisors LLCmarketbeat.com - August 11 at 10:22 PMKeros Therapeutics, Inc. (NASDAQ:KROS) to Post Q3 2023 Earnings of ($1.46) Per Share, HC Wainwright Forecastsmarketbeat.com - August 10 at 7:11 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Cigna (CI), Keros Therapeutics (KROS) and Qiagen (QGEN)markets.businessinsider.com - August 9 at 8:15 AMTruist Financial Remains a Buy on Keros Therapeutics (KROS)markets.businessinsider.com - August 9 at 3:15 AMWedbush Reiterates Keros Therapeutics (KROS) Outperform Recommendationmsn.com - August 8 at 5:14 PMKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Resultsfinanznachrichten.de - August 8 at 2:09 AMWedbush Sticks to Its Buy Rating for Keros Therapeutics (KROS)markets.businessinsider.com - August 8 at 2:09 AMKeros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 7 at 8:30 AMKeros Therapeutics: Hematological Therapies Continue To Advanceseekingalpha.com - August 2 at 1:19 PMWedbush Initiates a Buy Rating on Keros Therapeutics (KROS)markets.businessinsider.com - July 31 at 11:54 AMCorrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertensionfinance.yahoo.com - July 27 at 8:39 PMWhere Keros Therapeutics Stands With Analystsmarkets.businessinsider.com - July 26 at 9:53 PMKeros Therapeutics (NASDAQ:KROS) Now Covered by Analysts at Bank of Americamarketbeat.com - July 26 at 5:53 PMKeros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertensionfinance.yahoo.com - July 24 at 9:28 AMKeros Therapeutics (NASDAQ: KROS)fool.com - July 23 at 8:10 AMShort Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Expands By 19.7%marketbeat.com - June 16 at 6:55 PMKeros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conferencefinance.yahoo.com - June 12 at 4:54 PMH.C. Wainwright Remains a Buy on Keros Therapeutics (KROS)markets.businessinsider.com - June 9 at 12:36 PMKeros Therapeutics, Inc. (NASDAQ:KROS) Position Decreased by CIBC Asset Management Incmarketbeat.com - June 9 at 8:05 AMKeros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Associationfinance.yahoo.com - June 9 at 7:35 AMGSA Capital Partners LLP Makes New $392,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - June 8 at 6:16 AMKeros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conferencefinance.yahoo.com - June 7 at 10:15 AMPrincipal Financial Group Inc. Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - June 7 at 5:27 AMUBS Group AG Has $2.36 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - June 4 at 4:30 AM21,222 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Purchased by HRT Financial LPmarketbeat.com - June 1 at 6:43 AMKeros Therapeutics (KROS) Receives a Rating Update from a Top Analystmarkets.businessinsider.com - May 29 at 6:18 PMOpaleye Management Inc. Has $11.43 Million Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - May 26 at 2:49 PM4,360 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Purchased by Arizona State Retirement Systemmarketbeat.com - May 25 at 4:29 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Rain Therapeutics (RAIN) and Keros Therapeutics (KROS)markets.businessinsider.com - May 23 at 12:45 AMKeros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conferencefinance.yahoo.com - May 22 at 9:44 AMRussell Investments Group Ltd. Purchases 16,348 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - May 22 at 5:18 AMCitigroup Inc. Sells 64,020 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - May 16 at 6:17 AMTD Asset Management Inc Invests $480,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - May 12 at 4:42 AMKeros Therapeutics to Present at the 28th Annual Congress of the European Hematology Associationfinance.yahoo.com - May 11 at 5:42 PMHC Wainwright & Co. Reiterates Keros Therapeutics (KROS) Buy Recommendationmsn.com - May 9 at 8:51 AMAnalysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Keros Therapeutics (KROS)markets.businessinsider.com - May 8 at 8:20 AMKeros Therapeutics GAAP EPS of -$1.26seekingalpha.com - May 7 at 3:01 PMPiper Sandler Maintains Keros Therapeutics (KROS) Overweight Recommendationnasdaq.com - May 6 at 7:53 AMKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Resultsfinanznachrichten.de - May 5 at 4:05 PMKeros Therapeutics (NASDAQ:KROS) Releases Earnings Resultsmarketbeat.com - May 5 at 12:53 PMProShare Advisors LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - May 5 at 4:42 AM Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Media Mentions By Week KROS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼1.810.41▲Average Medical News Sentiment KROS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼21▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Deciphera Pharmaceuticals News Acelyrin News Pliant Therapeutics News Avadel Pharmaceuticals News Ardelyx News Morphic News Ligand Pharmaceuticals News Innoviva News Belite Bio News Pharming Group News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:KROS) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.